Russell Barton
Known title: Chief Operating OfficerCIK: 0001867418
Associated companies
Transaction History
| ABOS | ▼ Sell | Open Market | 462 | $850 | 1/22/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 2,315 | $4K | 1/21/2026 | View on chart |
| ABOS | ▲ Buy | Grant | 84,600 | $0 | 1/16/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 3,530 | $7K | 1/8/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 1,700 | $3K | 1/7/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 3,618 | $7K | 1/6/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 4,000 | $8K | 1/5/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 2,914 | $5K | 1/21/2025 | View on chart |
| ABOS | ▲ Buy | Grant | 49,800 | $0 | 1/6/2025 | View on chart |
| ABOS | ▼ Sell | Open Market | 7,636 | $14K | 1/3/2025 | View on chart |
| ABOS | ▼ Sell | Open Market | 2,833 | $11K | 1/18/2024 | View on chart |
| ABOS | ▲ Buy | Grant | 73,000 | $0 | 1/2/2024 | View on chart |
| ABOS | ▲ Buy | Grant | 26,700 | $0 | 1/17/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Acumen Pharmaceuticals Featured in Alzheimer's Day Stock List
Acumen Pharmaceuticals was included in a Yahoo Finance article highlighting four Alzheimer's drug stocks to watch on World Alzheimer's Day. The mention serves as a reminder of the company's focus on neurodegenerative diseases, though the article does not report any new clinical data or corporate announcements. The stock is currently trading near its 52-week low, with an average analyst target of $7.60.
Acumen Pharmaceuticals Featured in Alzheimer's Day Stock List. Acumen Pharmaceuticals was included in a Yahoo Finance article highlighting four Alzheimer's drug stocks to watch on World Alzheimer's Day. The mention serves as a reminder of the company's focus on neurodegenerative diseases, though the article does not report any new clinical data or corporate announcements. The stock is currently trading near its 52-week low, with an average analyst target of $7.60.